Reviewing scPharmaceuticals Inc. (SCPH)’s and Allakos Inc. (NASDAQ:ALLK)’s results

Both scPharmaceuticals Inc. (NASDAQ:SCPH) and Allakos Inc. (NASDAQ:ALLK) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to risk, analyst recommendations, profitability, dividends, institutional ownership, earnings and valuation.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
scPharmaceuticals Inc. N/A 0.00 31.22M -1.68 0.00
Allakos Inc. N/A 0.00 36.89M -0.90 0.00

Table 1 shows top-line revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 provides us scPharmaceuticals Inc. and Allakos Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
scPharmaceuticals Inc. 0.00% -33.2% -28.4%
Allakos Inc. 0.00% 0% 0%

Liquidity

The Current Ratio and a Quick Ratio of scPharmaceuticals Inc. are 13 and 13. Competitively, Allakos Inc. has 24.4 and 24.4 for Current and Quick Ratio. Allakos Inc.’s better ability to pay short and long-term obligations than scPharmaceuticals Inc.

Insider and Institutional Ownership

scPharmaceuticals Inc. and Allakos Inc. has shares held by institutional investors as follows: 78.3% and 83.3%. About 17.25% of scPharmaceuticals Inc.’s share are held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
scPharmaceuticals Inc. -1.49% 1.09% -9.41% -35.83% -66.67% -61.79%
Allakos Inc. 6.35% 9.34% 45.87% 0% 0% 100.48%

For the past year scPharmaceuticals Inc. had bearish trend while Allakos Inc. had bullish trend.

Summary

Allakos Inc. beats scPharmaceuticals Inc. on 5 of the 6 factors.

scPharmaceuticals Inc., biopharmaceutical company, engages in the development and commercialization of transformative pharmaceutical products. The company's under development products are for heart failure and infectious diseases that include Furoscix that is for treatment of worsening or decompensated heart failure outside of the inpatient setting. scPharmaceuticals Inc. formerly known as scPharmaceuticals LLC. and changed its name to scPharmaceuticals Inc. in March 2014. The company was founded 2013 and is based in Burlington, Massachusetts.

Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in San Carlos, California.